Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. DPZ
4. ACN
5. DFTX
6. IBM
7. META
8. AISP
9. KFY
10. SPY

Go back to Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics (ALDX) to Resume Trading at 7:30 a.m.

April 27, 2021 7:16 AM EDT

Aldeyra Therapeutics (NASDAQ: ALDX) to Resume Trading at 7:30 a.m.

... More